ArticleAJOG global reports2026
Chromosome 17q12 deletion, including
Article in AJOG global reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: 17q12 deletion features kidney/genital abnormalities, maturity-onset diabetes of the young, and bile duct hypoplasia. The condition may first present with severe cholestasis during pregnancy, and is important to differentiate from classic intrahepatic cholestasis of pregnancy. Case Presentation: A 30-year-old G3P0202 was referred at 27 weeks' gestation with generalized weakness exacerbated in pregnancy. Obstetric history was significant for two prior spontaneous preterm births in the setting of a bicornuate uterus. The patient had severe cholestasis during both prior pregnancies. Family history is significant for a son with severe hydronephrosis and autism. The patient's laboratories revealed critically low serum magnesium with severely elevated 24-hour-urine magnesium, suggesting renal magnesium wasting. She was treated with ongoing magnesium infusions. She was also diagnosed with severe cholestasis and gestational diabetes, and ultimately induced at 33 weeks due to intractable pruritus. The infant had a 35-day stay in the neonatal intensive care unit. Maternal chromosomal microarray returned with a pathogenic deletion of 17q12. The patient was advised to have her children evaluated with a geneticist. Conclusion: 17q12 deletion was the likely etiology of recurrent severe cholestasis complicating our patient's prior pregnancies, and in the current pregnancy, along with renal dysfunction. Knowledge of 17q12 deletion is important for counseling of affected reproductive-aged women at risk of stillbirth associated with severe cholestasis and renal dysfunction during pregnancy. 17q12 deletion should be considered in the differential diagnosis when severely elevated bile acids are encountered during pregnancy, particularly in combination with maternal Mullerian anomaly or renal dysfunction, or fetal renal anomaly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.